Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study

A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria

How does long term treatment with Soliris affect HAHA in PNH patients?

To determine the long term effect of Soliris (eculizumab) treatment on the presence of human anti-human antibodies (HAHA) in Paroxysmal Nocturnal Hemoglobinuria (PNH) patients.

Inclusion Criteria:

• PNH patients who previously participated in study E05-001;
• Patients who have an eculizumab naive serum sample for comparison;
• Patients who currently used commerical Soliris;
• Patients who are willing and able to gie written informed consent.

Exclusion Criteria:

• There are no exclusion criteria for this study.